Payment overview · 2025
General Payments
$2,750.96
116 reported records · 16 companies
Healthcare provider profile · identity verified
Chang Suk Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1154417871
Verified facts
What the public records show
CMS Open Payments records show Chang Suk Lee, M.D. received $2,750.96 in general payments during 2025 across 116 reported records.
Amgen Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Linzess, Ozempic, Rybelsus, Trelegy Ellipta, Vemlidy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 1796 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 358 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $523.64 | 19.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $416.63 | 15.1% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $326.95 | 11.9% | 33 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $253.22 | 9.2% | 21 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $192.30 | 7.0% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $188.12 | 6.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $172.63 | 6.3% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $165.88 | 6.0% | 14 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $119.81 | 4.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $118.73 | 4.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $108.47 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.39 | 2.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.93 | 1.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.84 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.98 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.44 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,750.96 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $375.00 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $326.95 | 33 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $326.95 | 33 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $303.52 | 9 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $253.22 | 21 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $243.68 | 8 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $192.30 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $188.12 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $172.63 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $165.88 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $148.64 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $119.81 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $118.73 | 1 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $108.47 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.39 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.41 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 1796 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 274 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 326 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
1796 | 231 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
274 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
326 | 52 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
202 | 112 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
55 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
358 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 4861 | 686 |
| Vascepa | Icosapent Ethyl | 3370 | 361 |
| Amlodipine Besylate | Amlodipine Besylate | 3116 | 414 |
| Losartan Potassium | Losartan Potassium | 2230 | 316 |
| Escitalopram Oxalate | Escitalopram Oxalate | 2024 | 283 |
| Creon | Lipase/Protease/Amylase | 1796 | 231 |
| Simvastatin | Simvastatin | 1526 | 207 |
| Metformin Hcl | Metformin Hcl | 1487 | 215 |
| Diclofenac Epolamine | Diclofenac Epolamine | 1386 | 172 |
| Raloxifene Hcl | Raloxifene Hcl | 1334 | 170 |
| Zolpidem Tartrate | Zolpidem Tartrate | 1320 | 284 |
| Omeprazole | Omeprazole | 1314 | 198 |
| Lidocaine | Lidocaine | 1163 | 177 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1126 | 153 |
| Donepezil Hcl | Donepezil Hcl | 1059 | 129 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 1001 | 136 |
| Celecoxib | Celecoxib | 914 | 114 |
| Allopurinol | Allopurinol | 909 | 134 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 751 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 726 | 98 |
| Meloxicam | Meloxicam | 698 | 111 |
| Meclizine Hcl | Meclizine Hcl | 634 | 150 |
| Azithromycin | Azithromycin | 632 | 374 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 598 | 82 |
| Fenofibrate | Fenofibrate,micronized | 575 | 76 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 561 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 534 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 68 |
| Glipizide Er | Glipizide | 502 | 80 |
| Ibuprofen | Ibuprofen | 500 | 217 |
| Clopidogrel | Clopidogrel Bisulfate | 488 | 73 |
| Januvia | Sitagliptin Phosphate | 480 | 65 |
| Montelukast Sodium | Montelukast Sodium | 455 | 58 |
| Myrbetriq | Mirabegron | 426 | 49 |
| Dexlansoprazole Dr | Dexlansoprazole | 375 | 52 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 373 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 362 | 54 |
| Jardiance | Empagliflozin | 358 | 40 |
| Glimepiride | Glimepiride | 345 | 51 |
| Lisinopril | Lisinopril | 343 | 50 |
| Atenolol | Atenolol | 339 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 334 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 333 | 45 |
| Zenpep | Lipase/Protease/Amylase | 326 | 52 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 321 | 39 |
| Ibandronate Sodium | Ibandronate Sodium | 308 | 39 |
| Ammonium Lactate | Ammonium Lactate | 288 | 52 |
| Linzess | Linaclotide | 274 | 35 |
| Gabapentin | Gabapentin | 256 | 50 |
| Finasteride | Finasteride | 249 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 235 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 234 | 33 |
| Carvedilol | Carvedilol | 221 | 27 |
| Famotidine | Famotidine | 219 | 37 |
| Solifenacin Succinate | Solifenacin Succinate | 219 | 26 |
| Alendronate Sodium | Alendronate Sodium | 217 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 35 |
| Amoxicillin | Amoxicillin | 202 | 121 |
| Prolia | Denosumab | 202 | 112 |
| Alprazolam | Alprazolam | 194 | 52 |
| Trazodone Hcl | Trazodone Hcl | 190 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 189 | 30 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 188 | 56 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 182 | 31 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 177 | 33 |
| Procto-Med Hc | Hydrocortisone | 177 | 33 |
| Mometasone Furoate | Mometasone Furoate | 170 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 23 |
| Sertraline Hcl | Sertraline Hcl | 165 | 26 |
| Metformin Hcl Er | Metformin Hcl | 158 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 144 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 140 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 136 | 18 |
| Tradjenta | Linagliptin | 134 | 14 |
| Econazole Nitrate | Econazole Nitrate | 133 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 123 | 29 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 119 | 46 |
| Fenofibrate | Fenofibrate | 116 | 17 |
| Eliquis | Apixaban | 115 | 21 |
| Nifedipine Er | Nifedipine | 113 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 108 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 20 |
| Ketoconazole | Ketoconazole | 105 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 15 |
| Memantine Hcl Er | Memantine Hcl | 99 | 12 |
| Azelastine Hcl | Azelastine Hcl | 98 | 19 |
| Icosapent Ethyl | Icosapent Ethyl | 96 | 52 |
| Loperamide | Loperamide Hcl | 96 | 60 |
| Naproxen | Naproxen | 95 | 21 |
| Hydrocortisone | Hydrocortisone | 93 | 23 |
| Diclofenac Potassium | Diclofenac Potassium | 90 | 13 |
| Enalapril Maleate | Enalapril Maleate | 90 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 86 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 86 | 23 |
| Dexilant | Dexlansoprazole | 84 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 83 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 12 |
| Gemfibrozil | Gemfibrozil | 77 | 13 |
| Valsartan | Valsartan | 77 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 74 | 11 |
| Lubiprostone | Lubiprostone | 71 | suppressed |
| Telmisartan | Telmisartan | 71 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 70 | 11 |
| Lorazepam | Lorazepam | 68 | 20 |
| Rybelsus | Semaglutide | 67 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 50 |
| Metoclopramide Hcl | Metoclopramide Hcl | 63 | 29 |
| Furosemide | Furosemide | 62 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 23 |
| Trintellix | Vortioxetine Hydrobromide | 62 | suppressed |
| Mupirocin | Mupirocin | 60 | 29 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | suppressed |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 57 | 14 |
| Farxiga | Dapagliflozin Propanediol | 57 | suppressed |
| Ozempic | Semaglutide | 57 | suppressed |
| Lansoprazole | Lansoprazole | 56 | suppressed |
| Proctozone-Hc | Hydrocortisone | 56 | suppressed |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 42 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | suppressed |
| Sucralfate | Sucralfate | 53 | 21 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | suppressed |
| Spironolactone | Spironolactone | 51 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | suppressed |
| Felodipine Er | Felodipine | 48 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 48 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 47 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 46 | 17 |
| Acyclovir | Acyclovir | 45 | 12 |
| Cilostazol | Cilostazol | 45 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 45 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 43 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Glipizide Xl | Glipizide | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Nexium | Esomeprazole Magnesium | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Livalo | Pitavastatin Calcium | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Fluocinonide | Fluocinonide | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Colchicine | Colchicine | 32 | suppressed |
| Belsomra | Suvorexant | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 31 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Minoxidil | Minoxidil | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Edarbi | Azilsartan Medoxomil | 27 | suppressed |
| Prednisone | Prednisone | 27 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| True Comfort Alcohol Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Tavaborole | Tavaborole | 24 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | 12 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 22 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Ibu | Ibuprofen | 17 | 13 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cimetidine | Cimetidine | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl Er | Cyclobenzaprine Hcl | 15 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Imiquimod | Imiquimod | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amcinonide | Amcinonide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,750.96 · 116 records | Amgen Inc. | AIRSUPRA, CAPVAXIVE, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, IBSRELA, LINZESS, Leqembi, MOUNJARO, Nubeqa, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Vemlidy, ZENPEP, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error